LOS ANGELES – Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that all six facial products of the Seratopical Revolution skincare line will be available for purchase at CVS in the Fall of 2021. CVS is one of the leading national drug store chains in America.

Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products. The line’s P3P complex, developed by CURE Pharmaceutical, drives natural, clean, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution’s natural oil and surfactant delivery systems are highly efficacious and offer near immediate results.

Nancy Duitch, Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer, stated, “There are a lot of beauty companies, but the problem is that most of them don’t understand that without an effective delivery system, the products are sitting on top of your skin and clogging your pores. Our formulators have developed a proprietary high-tech delivery system which allows the ingredients to go deep into the skin. Our loyal customers will benefit from scientifically backed ingredients that are designed to enhance hydration and rejuvenate collagen. Our Seratopical Revolution facial products possess these unique problem-solving attributes married with beautiful packaging that stands out on the shelf and our partnership with one of the most respected and recognized actors in the world: Nicole Kidman – as strategic partner and global brand ambassador – making our company and brand a fierce competitor in the beauty industry.”

“This is another fantastic branding and expansion opportunity for our company and its product line. We created Seratopical Revolution to meet the needs of a wide base of customers, for all people of all skin types who are seeking to explore truly innovative and cutting-edge skincare product options. Having our skincare line available at CVS for customers to purchase bolsters our national presence and demonstrates the ever-expanding retailer support,” stated John Cammarano, Sera Labs Sr. Vice President of Marketing and Sales.

Cammarano continued, “We have only just begun to build our successful brand by exploiting multiple channels of marketing which will not only create awareness but will always be ROI driven. Given that there are a lot of beauty companies available for retail merchants to consider, we are excited that CVS has given the Seratopical Revolution product line a premiere location regarding shelf space and our products will reside in-between two of the worlds most recognized brands giving our company the opportunity to acquire new customers and drive sales.”

About CVS

CVS is America’s leading retail pharmacy with nearly 10,000 locations, including over 1,700 pharmacies inside of Target and Schnucks grocery stores. We are committed to delivering innovative health solutions that create a simpler, more accessible experience for patients, customers and caregivers. CVS is the only national pharmacy to remove tobacco products from its shelves and has taken a leadership role in responding to the COVID-19 pandemic by making testing and vaccinations available at locations across the United States. For the latest product and service offerings, visit www.cvs.com or download the CVS Pharmacy app.

About Sera Labs

Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, and SeraLabs™, Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: press@theseralabs.com.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.

These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contact:

Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

Investor Contact: